AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17929072 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-34PTH + raloxifene
Number of subjects: 42
Study 17929072 — intervention group
Group type: COMPARATOR
Intervention: raloxifene alone
Number of subjects: 42
Study 16183427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg) plus insulin
Number of subjects: 52
Study 16183427 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (control)
Number of subjects: 52
Study 12955901 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel antipsychotic drugs
Number of subjects: 80
Study 12955901 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication
Number of subjects: 80
Study 10727880 — intervention group
Group type: EXPERIMENTAL
Intervention: co-artemether alone
Number of subjects: 42
Study 10727880 — intervention group
Group type: EXPERIMENTAL
Intervention: mefloquine alone
Number of subjects: 42
Study 10727880 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of co-artemether and mefloquine
Number of subjects: 42
Study 8855983 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2, 3 x 10(6) IU m‐2 day‐1, subcutaneously for 3 months
Number of subjects: 39
Study 8855983 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2, 5.4 x 10(6) IU m‐2 day‐1, subcutaneously for 3 months
Number of subjects: 39
Study 8855983 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 with levamisole (50 mg t.d.s. p.o. on days 1-3 on alternate weeks)
Number of subjects: 39
Study 8855983 — intervention group
Group type: COMPARATOR
Intervention: IL-2 without levamisole
Number of subjects: 39
Study 1643799 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Insulin (HI)
Number of subjects: 8
Study 1643799 — intervention group
Group type: COMPARATOR
Intervention: Porcine Insulin (PI)
Number of subjects: 8
Study 6592321 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy-Jet
Number of subjects: 0
Study 6592321 — intervention group
Group type: COMPARATOR
Intervention: Rubber cup and prophylaxis paste
Number of subjects: 0
Study 31214914 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 2733
Study 31214914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2733
Study 30575489 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg)
Number of subjects: 2000
Study 30575489 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 2000
Study 27798337 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS + 0.2 g 2'‐FL/L
Number of subjects: 317
Study 27798337 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS + 1.0 g 2'‐FL/L
Number of subjects: 317
Study 27798337 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed
Number of subjects: 317
Study 27798337 — intervention group
Group type: COMPARATOR
Intervention: Control formula (GOS only)
Number of subjects: 317
Study 25312197 — intervention group
Group type: EXPERIMENTAL
Intervention: Demodex folliculorum positive patients
Number of subjects: 180
Study 25312197 — intervention group
Group type: COMPARATOR
Intervention: Demodex folliculorum negative patients
Number of subjects: 180
Study 22076016 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) measurement of the triple marker panel of cardiac troponin I (cTnI), myoglobin, and CK-MB on admission and 90 min from admission.
Number of subjects: 1125
Study 22076016 — intervention group
Group type: COMPARATOR
Intervention: Central laboratory testing for biomarkers (control group).
Number of subjects: 1125
Study 20061328 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) capsules, 1240 mg eicosapentaenoic acid and 1000 mg docosahexaenoic acid, for 5-7 days prior to surgery and post-operatively until hospital discharge
Number of subjects: 170
Study 20061328 — intervention group
Group type: COMPARATOR
Intervention: Olive oil capsules for 5-7 days prior to surgery and post-operatively until hospital discharge
Number of subjects: 170
Study 18672751 — intervention group
Group type: EXPERIMENTAL
Intervention: Robert Jones Bandage
Number of subjects: 48
Study 18672751 — intervention group
Group type: COMPARATOR
Intervention: U splint
Number of subjects: 48
Study 18672751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 15983231 — intervention group
Group type: EXPERIMENTAL
Intervention: Arg72Thr variant of PYY
Number of subjects: 84
Study 15983231 — intervention group
Group type: EXPERIMENTAL
Intervention: Arg allele of PYY
Number of subjects: 84
Study 12433819 — intervention group
Group type: EXPERIMENTAL
Intervention: R (ritonavir) 400 mg given simultaneously with S (saquinavir) 800 mg
Number of subjects: 18
Study 12433819 — intervention group
Group type: EXPERIMENTAL
Intervention: N (nelfinavir) 750 mg given simultaneously with S (saquinavir) 800 mg
Number of subjects: 18
Study 12433819 — intervention group
Group type: EXPERIMENTAL
Intervention: R (ritonavir) 400 mg
Number of subjects: 18
Study 10725786 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (2 mg/kg/day) for 12 weeks
Number of subjects: 25
Study 10725786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7795774 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% selenium sulfide lotion
Number of subjects: 54
Study 7795774 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% selenium sulfide shampoo
Number of subjects: 54
Study 7795774 — intervention group
Group type: COMPARATOR
Intervention: Nonmedicated control shampoo
Number of subjects: 54
Study 1954072 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for 11 days
Number of subjects: 10
Study 1954072 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 1 mg alone (control)
Number of subjects: 10
Study 7007474 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseasonal intranasal short ragweed (SRW) immunotherapy, sprayed SRW solutions intranasally six times a day for 12 weeks
Number of subjects: 33
Study 7007474 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseasonal intranasal short ragweed (SRW) immunotherapy
Number of subjects: 33
Study 7007474 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with nebulized solutions containing buffer or histamine
Number of subjects: 33
Study 31402321 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole plus taselisib (4 mg orally, on a 5 days-on, 2 days-off schedule for 16 weeks)
Number of subjects: 334
Study 31402321 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole plus taselisib
Number of subjects: 334
Study 31402321 — intervention group
Group type: COMPARATOR
Intervention: Letrozole plus placebo
Number of subjects: 334
Study 28647383 — intervention group
Group type: EXPERIMENTAL
Intervention: Agaricus bisporus mushrooms (226 g)
Number of subjects: 32
Study 28647383 — intervention group
Group type: COMPARATOR
Intervention: Meat (28 g)
Number of subjects: 32
Study 25210140 — intervention group
Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 bivalent vaccine-like particle (VLP) vaccine with 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and alum
Number of subjects: 98
Study 25210140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 25210140 — intervention group
Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 bivalent vaccine-like particle (VLP) vaccine
Number of subjects: 98
Study 22809633 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2.0mm conventional titanium miniplate (Group-I)
Number of subjects: 20
Study 22809633 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2.0mm three-dimensional titanium miniplate (Group-II)
Number of subjects: 20
Study 21083671 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 4 weeks (n = 28)
Number of subjects: 108
Study 21083671 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 108
Study 21083671 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg
Number of subjects: 108
Study 21083671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 19305326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampon Test
Number of subjects: 0
Study 17680954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver group (processed shed autologous blood and homologous blood if necessary)
Number of subjects: 49
Study 17680954 — intervention group
Group type: COMPARATOR
Intervention: Non-cell saver group (transfused homologous blood only)
Number of subjects: 49
Study 15058123 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use SoftSeal laryngeal mask (n = 99)
Number of subjects: 200
Study 15058123 — intervention group
Group type: COMPARATOR
Intervention: Reusable LMA Classic laryngeal mask (n = 100)
Number of subjects: 200
Study 15058123 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use SoftSeal laryngeal mask
Number of subjects: 200
Study 15058123 — intervention group
Group type: COMPARATOR
Intervention: Reusable LMA Classic laryngeal mask
Number of subjects: 200
Study 11498488 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and Vitamin A supplementation
Number of subjects: 800
Study 11498488 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 800
Study 11498488 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Zinc and Vitamin A
Number of subjects: 800
Study 11498488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 11045875 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 0
Study 11045875 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 microg
Number of subjects: 0
Study 11045875 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9346980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with moderated fat intake (25 to 30 E%)
Number of subjects: 848
Study 9346980 — intervention group
Group type: COMPARATOR
Intervention: Control group with free diet
Number of subjects: 848
Study 9346980 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin children (mean relative weight ≤ 5%)
Number of subjects: 848
Study 9346980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tall children (mean relative height ≥ 95%)
Number of subjects: 848
Study 9346980 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children (mean relative weight ≥ 95%)
Number of subjects: 848
Study 9346980 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin children
Number of subjects: 848
Study 8478410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline
Number of subjects: 30
Study 8478410 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 4035228 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg/day
Number of subjects: 0
Study 4035228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30779339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 35 mg
Number of subjects: 2
Study 30779339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 105 mg
Number of subjects: 2
Study 30779339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 210 mg
Number of subjects: 2
Study 30779339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 210 mg every 28 days
Number of subjects: 2
Study 30779339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 210 mg every 14 days
Number of subjects: 2
Study 30779339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157) 210 mg every 7 days
Number of subjects: 2
Study 30779339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (AMG 157)
Number of subjects: 2
Study 30011053 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis
Number of subjects: 30
Study 30011053 — intervention group
Group type: COMPARATOR
Intervention: Conventional plate osteosynthesis
Number of subjects: 30
Study 30011053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 26156560 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 (phylloquinone) 10 mg/day for 8 weeks
Number of subjects: 64
Study 26156560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24909155 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Coat One F (MSC)
Number of subjects: 50
Study 24909155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoseal (NAN)
Number of subjects: 50
Study 24909155 — intervention group
Group type: EXPERIMENTAL
Intervention: Teethmate Desensitizer (TMD)
Number of subjects: 50
Study 24909155 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer PowerGel (GLU)
Number of subjects: 50
Study 22673254 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Number of subjects: 73
Study 22673254 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed weaning
Number of subjects: 73
Study 20119859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberry juice
Number of subjects: 62
Study 20119859 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 62
Study 18606034 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 3
Study 18606034 — intervention group
Group type: COMPARATOR
Intervention: Developmental Education for Families (control intervention)
Number of subjects: 3
Study 18606034 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison group (children who have never been in foster care)
Number of subjects: 3
Study 16078928 — intervention group
Group type: EXPERIMENTAL
Intervention: Trima Accel
Number of subjects: 51
Study 16078928 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicus Crescendo
Number of subjects: 51
Study 16078928 — intervention group
Group type: EXPERIMENTAL
Intervention: MCS Plus
Number of subjects: 51
Study 16078928 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor preference
Number of subjects: 51
Study 12417283 — intervention group
Group type: EXPERIMENTAL
Intervention: apo A‐I <1.2 g/l
Number of subjects: 507
Study 12417283 — intervention group
Group type: EXPERIMENTAL
Intervention: apo B > or =1.4 g/l
Number of subjects: 507
Study 12417283 — intervention group
Group type: EXPERIMENTAL
Intervention: apo B/apo A‐I ratio > or =1
Number of subjects: 507
Study 12417283 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 507
Study 12417283 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐Hispanics
Number of subjects: 507
Study 12417283 — intervention group
Group type: EXPERIMENTAL
Intervention: high density lipoprotein cholesterol
Number of subjects: 507
Study 10420248 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracket removing pliers
Number of subjects: 507
Study 10420248 — intervention group
Group type: COMPARATOR
Intervention: Lift off debonding instrument (LODI)
Number of subjects: 507
Study 7745931 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholecystoenteric anastomosis with transhepatic drain (group I)
Number of subjects: 187
Study 7745931 — intervention group
Group type: COMPARATOR
Intervention: Precision anastomosis (group II)
Number of subjects: 187
Study 2200382 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/d)
Number of subjects: 394
Study 2200382 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg every 12 hours)
Number of subjects: 394
Study 2200382 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil sustained release (240 mg/d)
Number of subjects: 394
Study 31563659 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake sedation with target controlled propofol infusion
Number of subjects: 47
Study 31563659 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam premedication only
Number of subjects: 47
Study 30472337 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% capsaicin lotion
Number of subjects: 42
Study 30472337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27799019 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS plus WPFM
Number of subjects: 107
Study 27799019 — intervention group
Group type: COMPARATOR
Intervention: IPS only
Number of subjects: 107
Study 27799019 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 107
Study 27799019 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 107
Study 25980737 — intervention group
Group type: COMPARATOR
Intervention: Standard RDT training
Number of subjects: 29223
Study 25980737 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Worker (HW) arm
Number of subjects: 29223
Study 25980737 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Worker-Patient (HWP) arm
Number of subjects: 29223
Study 23371961 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-sensitive nephrotic syndrome
Number of subjects: 166
Study 23371961 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment
Number of subjects: 166
Study 23371961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression model
Number of subjects: 166
Study 21612513 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse diode (SDM) laser (810 nm)
Number of subjects: 33
Study 21612513 — intervention group
Group type: COMPARATOR
Intervention: Double-frequency neodymium YAG (Nd:YAG) laser (532 nm)
Number of subjects: 33
Study 19307442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 0
Study 19307442 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% policocanol foam
Number of subjects: 0
Study 19307442 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide foam
Number of subjects: 0
Study 17845617 — intervention group
Group type: EXPERIMENTAL
Intervention: New combined pruritus scale (features of behaviour and severity-based scales with visual analogue scale)
Number of subjects: 166
Study 17845617 — intervention group
Group type: COMPARATOR
Intervention: Severity scale
Number of subjects: 166
Study 17845617 — intervention group
Group type: COMPARATOR
Intervention: Numerical scale
Number of subjects: 166
Study 17845617 — intervention group
Group type: COMPARATOR
Intervention: Behaviour scale
Number of subjects: 166
Study 17845617 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent scores by two owners
Number of subjects: 166
Study 15519020 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenotic aortic valves
Number of subjects: 97
Study 15519020 — intervention group
Group type: COMPARATOR
Intervention: Control valves
Number of subjects: 97
Study 11816442 — intervention group
Group type: COMPARATOR
Intervention: Pentostam (sodium stibogluconate, GlaxoWellcome, London)
Number of subjects: 199
Study 11816442 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic sodium stibogluconate (SSG) (International Dispensary Association, Amsterdam)
Number of subjects: 199
Study 11816442 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV co-infected VL patients
Number of subjects: 199
Study 11816442 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients
Number of subjects: 199
Study 9747023 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselor support
Number of subjects: 36
Study 9747023 — intervention group
Group type: COMPARATOR
Intervention: No peer counselor support (Control)
Number of subjects: 36
Study 7805356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (1500 mg)
Number of subjects: 567
Study 7805356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (800 or 1000 mg)
Number of subjects: 567
Study 7805356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (400 or 500 mg)
Number of subjects: 567
Study 7805356 — intervention group
Group type: COMPARATOR
Intervention: Comparators (spectinomycin, thiamphenicol, ampicillin, or amoxicillin plus probenecid)
Number of subjects: 567
Study 7805356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil
Number of subjects: 567
Study 7805356 — intervention group
Group type: COMPARATOR
Intervention: Standard drugs
Number of subjects: 567
Study 3189218 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate and malic acids (CCM)
Number of subjects: 12
Study 3189218 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 12
Study 4902494 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% local guanethidine
Number of subjects: 0
Study 4902494 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 0
Study 29550525 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS treatment (1 mA, 3 sessions per week for 6 weeks)
Number of subjects: 26
Study 29550525 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 26
Study 27530996 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention delivered by trained health professionals, consisting of up to four sessions tailored to patient symptoms and distress.
Number of subjects: 902
Study 27530996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 902
Study 27530996 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 902
Study 25842223 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable procaine benzylpenicillin‐gentamicin
Number of subjects: 2333
Study 25842223 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 2333
Study 25842223 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 2333
Study 23850318 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized antiplatelet therapy according to CYP2C19 phenotype
Number of subjects: 600
Study 23850318 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiplatelet treatment
Number of subjects: 600
Study 21596876 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2 μg/kg/min (group HI)
Number of subjects: 90
Study 21596876 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 0.05 μg/kg/min (group LO)
Number of subjects: 90
Study 21596876 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mg/kg at induction followed by 10 mg/kg/h (group HM)
Number of subjects: 90
Study 21596876 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (group HM)
Number of subjects: 90
Study 21596876 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90